Colin Broom, formerly chief scientific offer at ViroPharma Inc, has become the chief executive of Vienna-based Nabriva Therapeutics AG which is developing antibiotics against both Gram-positive and Gram-negative infections. Dr Broom led science at ViroPharma which was acquired by Shire Plc in January 2014. Prior to that he worked in senior positions at Amgen Inc, Hoechst Marion Roussel and SmithKline Beecham. He holds a Bachelor of Science degree in pharmacology from University College, London and Bachelor of Medicine and Bachelor of Surgery degrees from St George’s Hospital Medical School, London.
Concurrent with the appointment, Nabriva is setting up a clinical development subsidiary in Philadelphia, Pennsylvania.
Nabriva announced the appointment on 3 September 2014.
Copyright 2014 Evernow Publishing Ltd